Compare AT&T Inc. (T) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AT&T Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? AT&T Inc. trades at $24.42 (market cap $167.88B), while State Street SPDR S&P Biotech ETF trades at $158.88. The key difference: AT&T Inc. pays a 4.53% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, AT&T Inc. nearer its low. Which is the better fit depends on your goals.
| T | XBI | |
|---|---|---|
Market Cap | $167.88B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $29.62 | $164.28 |
52-Week Low | $20.49 | $86.92 |
Enterprise Value | $313.20B | — |
Dividend Yield | 4.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AT&T (T) trades at $24.08, up 1.18% with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.65 exceeding expectations. Valuation remains attractive with a P/E of 8.1 and dividend yield of 4.7%. Recent developments include fiber expansion and AI initiatives, while cash flow improved to $15.1B in 2025. Technical indicators show bullish moving averages with resistance near $24-25.
Outlook remains positive with 15% upside to consensus price target of $27.69. Investment appeal includes strong cash flow generation, dividend sustainability, and ongoing network investments. Key risks include competitive pressure from SpaceX's wireless ambitions and execution challenges in fiber deployment. Analyst consensus leans bullish with 41% buy ratings versus 10% sell recommendations.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
